Research Paper Volume 14, Issue 10 pp 4586—4605
Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers
Figure 3. Prognosis analysis of ioTNL in multiple datasets. Kaplan-Meier estimator was used to visualize the survival of ioTNL-H group and ioTNL-L group in the NSCLC cohort (A), the SKCM cohort (B), the NPC cohort (C) and the ICC cohort (D). (E) Forest plot for the hazard ratios of ioTNL in four cohorts. Larger boxes indicate statistical significance.